par Suleiman, Mara;Marselli, Lorella;Cnop, Miriam ;Eizirik, Decio L. ;Luca, Carmela De;Femia, Francesca F.R.;Tesi, Marta;Guerra, Silvia Del;Marchetti, Piero
Référence International journal of molecular sciences, 23, 13, 7435
Publication Publié, 2022-07
Référence International journal of molecular sciences, 23, 13, 7435
Publication Publié, 2022-07
Article révisé par les pairs
Résumé : | Type 2 diabetes (T2D) has been considered a relentlessly worsening disease, due to the progressive deterioration of the pancreatic beta cell functional mass. Recent evidence indicates, however, that remission of T2D may occur in variable proportions of patients after specific treatments that are associated with recovery of beta cell function. Here we review the available information on the recovery of beta cells in (a) non-diabetic individuals previously exposed to metabolic stress; (b) T2D patients following low-calorie diets, pharmacological therapies or bariatric surgery; (c) human islets isolated from non-diabetic organ donors that recover from “lipo-glucotoxic” conditions; and (d) human islets isolated from T2D organ donors and exposed to specific treatments. The improvement of insulin secretion reported by these studies and the associated molecular traits unveil the possibility to promote T2D remission by directly targeting pancreatic beta cells. |